Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/10521
Title: | Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children | Authors: | Yesilkaya, S. Acikel, C. Fidanci, B.E. Polat, A. Sozeri, B. Ayaz, N.A. Makay, B.B. |
Keywords: | Adherence Colchicine Familial Mediterranean fever Scale adolescent adult Article child cohort analysis construct validity content validity disease assessment familial Mediterranean fever feasibility study female follow up human internal consistency major clinical study male Medication Adherence Scale medication compliance patient assessment priority journal process development test retest reliability Turk (people) validation process age interview preschool child qualitative research questionnaire reproducibility treatment outcome Turkey validation study immunosuppressive agent Adolescent Age Factors Child Child, Preschool Familial Mediterranean Fever Feasibility Studies Female Humans Immunosuppressive Agents Interviews as Topic Male Medication Adherence Qualitative Research Reproducibility of Results Surveys and Questionnaires Treatment Outcome |
Publisher: | Clinical and Experimental Rheumatology S.A.S. | Abstract: | Objective. To develop and assess the validity and reliability of an adherence scale concerning medical treatment in paediatric FMF patients. Methods. The Medication Adherence Scale in FMF Patients (MASIF) is a 18-item questionnaire that evaluates adherence to medication in four domains. Validation of the instrument was accomplished in paediatric FMF patients (aged 2-18 years) under medication at least for 6 months. The first step was to build up the scale through qualitative approach (with interviews using semi-structured questions). Validation analyses included assessment of feasibility, face and content validity; construct validity, internal consistency and test-retest reliability. Results. One hundred and fifty patients with FMF were enrolled in the study. The mean age of the patients was 11.11±4.02 years and 48.7% of them were male. The MASIF was found to be feasible and valid for both face and content. It correlated with the Morisky Medication Adherence Scale as a gold standard thereby demonstrating good construct validity (r=0.515, p < 0.001). Assessment of content validity identified four subscales. The internal consistency, Cronbach's alpha was 0.728. There was a positive and significant correlation between test and retest scores (r=0.843; p < 0.001). Also, a significant correlation between parents' and children's reports (r=0.781, p < 0.001). Conclusion. Based on these results, the use of this scale to assess and follow up the adherence to treatment in paediatric FMF patients under medical treatment is recommended. © Clinical and Experimental Rheumatology 2015. | URI: | https://hdl.handle.net/11499/10521 | ISSN: | 0392-856X |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
9
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
10
checked on Nov 16, 2024
Page view(s)
46
checked on Aug 24, 2024
Google ScholarTM
Check
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.